SIGA Technologies, Inc
(NASDAQ:SIGA)

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an orally administered antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technolog...

Website: http://www.siga.com

Founded: 1995

Full Time Employees: 41

CEO: Phillip Gomez

Sector: Healthcare

Industry: Biotechnology

Pharmaceuticals Monkeypox Vaccine

Share this website to your friends

• Market Cap:

• Exchange:

• Shs Outstanding:

• Employees:

• Beta:

• Return on Equity (ROE) ttm:

• Return on Assets (ROA) ttm:

• EPS ttm:

• Book value per Share:

• Cash per Share:

• Current ast per Share:

• P/E ttm:

• P/E forward:

• P/E ttm high:

• P/E ttm low:

• P/S ttm:

• P/B ttm:

• P/FCF ttm:

• PEG ratio:

• Cash Ratio ttm:

• Quick Ratio ttm:

• Current Ratio ttm:

• Gross Mgn ttm:

• EBITDA Mgn ttm:

• Operating Mgn ttm:

• Net Income Mgn ttm:

• Trailing Div yield:

• Forward Div yield:

• Payout Ratio ttm:

• Ex-Dividend date:

• Target Price High:

• Target Price Low:

• Target Price Mean:

• Number of Analysts:

• Debt Ratio ttm:

• Debt to Equity ttm:

• Total Net Debt:

At a glance:

Bull Thesis:

Bear Thesis:

Main Competitors:

Moat:

Income Statements:

Quarterly

Annual

Unit: USD	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31

revenues
product sales and supportive services	3,537,876	2,212,290	889,748	79,124,860	5,821,247	79,833,312	8,942,875	20,675,317	23,878,677	115,744,151	7,958,289	1,263,255	5,702,515	5,103,435	65,621,511	8,615,765	7,320,872	114,008,921	2,346,110	6,924,162	3,523,343	34,923,420	41,810,192	38,624,450	113,009	132,329	3,915,335		7,142,400	53,239	468,865,229
research and development	2,704,704	1,581,794	1,730,252	1,995,144	1,219,568	1,635,511	1,066,906	1,135,574	1,551,178	736,708	1,276,882	4,614,911	2,620,510	6,254,704	6,589,616	8,051,280	3,218,427	1,348,327	2,500,062	1,729,127	1,290,401	2,805,935	2,451,215	1,724,327	2,506,756	4,131,737	4,195,989	3,907,611	3,316,684	1,516,069	2,210,095	2,661,216	1,747,934	1,412,359	1,390,254	4,264,561	5,201,786	7,158,226	4,658,355	1,901,314	1,269,733	4,188,923	1,327,403	1,467,460	1,192,092	840,379	1,099,429	650,612	549,415	934,126	2,292,143	964,667	1,328,364	2,514,099	2,289,820	2,701,164	1,465,752	4,960,067	3,577,948	2,491,056	1,696,721	3,062,016	6,631,857	4,446,753	5,075,211	3,955,184	3,921,938	4,008,959	1,925,777	2,488,563	1,862,557	1,731,958	1,982,540
total revenues	6,242,580	3,794,084	2,620,000	81,120,004	7,040,815	81,468,823	10,009,781	21,810,891	25,429,855	116,480,859	9,235,171	5,878,166	8,323,025	11,358,139	72,211,127	16,667,045	10,539,299	115,357,248	4,846,172	8,653,289	4,813,744	37,729,355	44,261,407	40,348,777	2,619,765	4,264,066	8,111,324	3,907,611	10,459,084	1,569,308	471,075,324
yoy	-11.34%	-95.34%	-73.83%	271.92%	-72.31%	-30.06%	8.39%	271.05%	205.54%	925.53%	-87.21%	-64.73%	-21.03%	-90.15%	1390.07%	92.61%	118.94%	205.75%	-89.05%	-78.55%	83.75%	784.82%	445.67%	932.57%	-74.95%	171.72%	-98.28%
qoq	64.53%	44.81%	-96.77%	1052.14%	-91.36%	713.89%	-54.11%	-14.23%	-78.17%	1161.27%	57.11%	-29.37%	-26.72%	-84.27%	333.26%	58.14%	-90.86%	2280.38%	-44.00%	79.76%	-87.24%	-14.76%	9.70%	1440.17%	-38.56%	-47.43%	107.58%	-62.64%	566.48%	-99.67%
operating expenses
cost of sales and supportive services	2,940,884	2,989,610	1,002,083	25,554,462	157,738	14,131,721	1,620,510	12,311,685	3,225,314	14,803,945	896,537	974,420	1,150,187	881,375	3,948,974	882,096	4,720,116	15,271,766	83,276	995,990	250,848	4,332,341	5,559,215	4,796,768	109,094	130,197	737,274		915,367	102,703	95,166,271
selling, general and administrative	4,673,014	5,262,945	4,786,511	5,487,576	5,675,662	6,907,264	4,822,591	5,530,423	7,875,773	7,382,195	5,999,761	4,425,959	4,235,108	5,875,676	19,656,138	5,874,139	3,518,030	3,745,542	4,305,644	5,216,059	4,056,184	3,389,917	3,566,258	3,870,927	3,176,024	3,496,971	3,196,370	3,392,228	3,166,566	3,828,121	3,114,678	2,880,394	3,056,546	3,281,011	3,093,926	3,058,244	2,869,869	4,437,128	2,855,255	3,738,709	2,656,231	2,594,570	2,321,236	2,605,476	3,087,523	2,422,546	4,313,540	2,799,054	3,088,658	3,781,586	3,265,735	3,166,149	3,031,349	2,582,851	3,138,711	3,474,691	2,213,877	6,362,512	3,968,605	9,350,541	4,250,056	2,538,794	1,389,259	2,233,825	1,968,791	2,149,541	1,522,186	1,801,746	2,059,693	1,492,867	945,347	1,165,071	1,004,804
total operating expenses	11,563,744	13,293,819	12,842,579	35,440,135	9,296,213	24,382,877	9,467,694	20,731,052	14,154,456	24,803,775	10,544,415	10,516,533	10,431,331	13,162,835	29,338,094	13,596,334	11,978,180	21,332,256	7,790,061	8,652,187	6,803,151	10,926,023	11,363,188	11,551,641	6,617,820	7,733,491	7,450,745	5,612,861	8,267,130	7,110,458	102,190,175	6,370,907	6,282,845	6,283,036	7,041,039	8,323,099	9,470,956	13,766,681	12,720,519	11,186,241	8,329,144	22,141,406	4,955,800	5,800,130	6,231,807	18,394,281	182,827,596	5,397,121	6,187,850	7,447,317	7,855,759	6,597,431	7,134,974	7,772,711	7,685,619	9,033,527	7,014,713	12,729,001	9,621,092	13,598,975	8,158,161	7,309,106	9,043,519	7,469,447	8,116,153	7,684,204	6,541,340	6,599,035	4,866,205	5,035,995	3,996,935	3,799,165	3,970,434
operating income	-5,321,164	-9,499,735	-10,222,579	45,679,869	-2,255,398	57,085,946	542,087	1,079,839	11,275,399	91,677,084	-1,309,244	-4,638,367	-2,108,306	-1,804,696	42,873,033	3,070,711	-1,438,881	94,024,992	-2,943,889	1,102	-1,989,407	26,803,332	32,898,219	28,797,136	-3,998,055	-3,469,425	660,579	-1,705,250	2,191,954	-5,541,150	368,885,149	-3,709,691	-4,534,911	-4,870,677	-5,650,785	-4,058,538	-4,269,170	-6,608,455	-8,062,164	-9,284,927	-7,059,411	-17,952,483	-3,628,397	-4,332,670	-5,039,715	-17,553,902	-181,728,167	-4,746,509	-5,638,435	-6,513,191	-5,563,616	-5,632,764	-5,806,610	-5,258,612	-5,395,799	-6,332,363	-5,548,961	-7,768,934	-6,043,144	-11,107,919	-6,461,440	-4,247,090	-2,411,662	-3,022,694	-3,040,942	-3,729,020	-2,619,402	-2,509,076	-2,940,428	-2,547,432	-2,134,378	-2,067,207	-1,987,894
yoy	135.93%	-116.64%	-1985.78%	4130.25%	-120.00%	-37.73%	-141.40%	-123.28%	-634.81%	-5179.92%	-103.05%	-251.05%	46.52%	-101.92%	-1556.34%	278548.91%	-27.67%	250.80%	-108.95%	-100.00%	-50.24%	-872.56%	4880.21%	-1788.73%	-282.40%	-37.39%	-99.82%	-54.03%	-148.34%	13.77%	-6628.03%	-8.60%	6.22%	-26.30%	-29.91%	-56.29%	-39.53%	-63.19%	122.20%	114.30%	40.08%	2.27%	-98.00%	-8.72%	-10.62%	169.51%	3166.37%	-15.73%	-2.90%	23.86%	3.11%	-11.05%	4.64%	-32.31%	-10.71%	-42.99%	-14.12%	82.92%	150.58%	267.48%	112.48%	13.89%	-7.93%	20.47%	3.42%	46.38%	22.72%	21.38%	47.92%
qoq	-43.99%	-7.07%	-122.38%	-2125.36%	-103.95%	10430.77%	-49.80%	-90.42%	-87.70%	-7102.29%	-71.77%	120.00%	16.82%	-104.21%	1296.19%	-313.41%	-101.53%	-3293.90%	-267240.56%	-100.06%	-107.42%	-18.53%	14.24%	-820.28%	15.24%	-625.21%	-138.74%	-177.80%	-139.56%	-101.50%	-10043.82%	-18.20%	-6.89%	-13.81%	39.23%	-4.93%	-35.40%	-18.03%	-13.17%	31.53%	-60.68%	394.78%	-16.25%	-14.03%	-71.29%	-90.34%	3728.67%	-15.82%	-13.43%	17.07%	-1.23%	-2.99%	10.42%	-2.54%	-14.79%	14.12%	-28.58%	28.56%	-45.60%	71.91%	52.14%	76.11%	-20.21%	-0.60%	-18.45%	42.36%	4.40%	-14.67%	15.43%	19.35%	3.25%	3.99%
operating margin %	-85.24%	-250.38%	-390.17%	56.31%	-32.03%	70.07%	5.42%	4.95%	44.34%	78.71%	-14.18%	-78.91%	-25.33%	-15.89%	59.37%	18.42%	-13.65%	81.51%	-60.75%	0.01%	-41.33%	71.04%	74.33%	71.37%	-152.61%	-81.36%	8.14%	-43.64%	20.96%	-353.10%	78.31%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%
other income	1,277,480	1,535,883	1,866,693	1,592,304	1,684,983	1,496,181	1,330,505	1,317,996	1,942,437	1,191,026	883,148	1,190,705	890,629	677,233	258,975	72,373	23,322	25,117	26,252	24,235	25,568	62,859	24,932	31,931	412,363	588,644	759,881	737,577	736,129	78,789,531	5,067	144,152	2,235	4,970	2,021	8,066	4,419	1,768	30,756	58,489	11,311	13,379	12,483	10,877	5,464	4	5	1,051	5	8	5	1,382	103	192	94	74	162	632	329	2,006	-2,793					775			662	9,277	18,225	23,098	43,452
income before income taxes	-4,043,684	-7,963,852	-8,355,886	47,272,173	-570,415	58,582,127	1,872,592	2,397,835	13,217,836	92,868,110	-426,096	-3,447,662	-1,217,677	-1,127,463	43,132,008	3,192,643	-1,064,455	93,873,331	-3,984,159	467,606	-1,045,038	26,250,153	31,648,995	27,209,480	-11,600,035	-6,462,603	-1,569,569	-4,282,181	2,135,930	67,635,160	362,637,418	-7,048,415	-11,584,608	-12,739,076	-9,681,710	-7,408,612	-8,499,876	-10,434,708	-9,247,714	-9,564,381	-10,437,273	-19,870,154	-5,564,610	-6,485,089	-7,069,488	-19,464,720	-182,123,716	-4,723,279	-5,623,154	-6,022,090	-6,592,004	-5,027,416	-7,154,261	-4,968,678	-5,410,737	-6,007,277	-5,985,612
benefit for income taxes	589,432	-2,409,202.75	1,990,067		162,192	-1,008,590.5	-528,647	-565,219	-2,940,496	226,159.5	33,030	572,186	299,422	-2,635,898.75	-10,091,420		703,406	-20,666,303	870,801		232,933	-6,088,727	-7,461,038	-6,319,322	2,702,506	1,959,998	363,742	1,119,689	-506,153	-15,244,226	25,412,995		2,352	2,436,353	-134,668
net and comprehensive loss	-3,454,252												-918,255				-361,049				-812,105							-3,162,492				-7,051,264	-11,582,256	-10,302,723	-9,816,378	-7,501,437	-8,614,946	-10,439,900	-9,243,642	-9,565,851	-10,448,567
basic loss per share	-0.05												-0.01								-0.01							-0.04
diluted loss per share	-0.05												-0.01				-0.01				-0.02							-0.05	-0.02
weighted-average shares outstanding: basic	71,649,957	71,528,043	71,604,956	71,465,521	71,427,527	71,253,172	71,368,585	71,152,572	71,093,653	71,362,209	71,084,735	71,090,642	72,197,038	72,929,550	73,024,147	72,678,333	73,070,565	75,322,194	74,840,846	75,810,641	76,757,010	79,259,000	78,080,461	80,340,695	81,240,105	81,031,254	81,064,927	80,986,524	80,913,320	79,923,295	80,023,044											53,777,687				53,419,686				52,368,842				51,639,622	51,639,811	51,638,352		50,929,491													35,109,434	34,507,090
weighted-average shares outstanding: diluted	71,649,957	71,867,627	71,604,956	71,748,888	71,427,527	71,905,712	71,766,503	71,753,231	71,562,996	71,679,270	71,084,735	71,090,642	72,197,038	73,546,501	73,259,272	73,332,888	73,883,058	76,402,716	74,840,846	76,660,054	77,572,587	79,437,306	78,168,070	80,516,863	81,240,105	82,175,023	82,181,858	82,114,661	82,139,108	82,708,472	82,929,476											53,777,687				53,419,686				52,368,842				51,639,622	51,639,811	51,638,352		54,061,650	51,987,253	54,671,403
net and comprehensive income		-5,429,918	-6,365,819	35,483,103	-408,223	45,760,315	1,343,945	1,832,616	10,277,340	72,255,625	-393,066	-2,875,476		-811,794	33,040,588	2,037,062		73,207,028	-3,113,358	169,200		20,161,426	24,187,957	20,890,158	-8,897,529	-4,502,605	-1,205,827		1,629,777	52,390,934	388,050,413											-20,094,048	-5,630,520	-6,573,437	-7,153,319	-19,056,255	-240,076,761	-2,948,262	-3,381,859
basic income per share		0.1	-0.09	0.5	-0.01	0.048	0.02	0.03	0.14	-0.015	-0.01	-0.04		0.12	0.45	0.03		-0.013	-0.04			0.113	0.31	0.26	-0.11	-0.008	-0.01
diluted income per share		0.1	-0.09	0.49	-0.01	0.048	0.02	0.03	0.14	-0.015	-0.01	-0.04		0.118	0.45	0.03		-0.013	-0.04			0.113	0.31	0.26		-0.023	-0.03
provision for income taxes				-11,789,070												-1,155,581				-298,406												-2,849				-92,825	-115,070			-1,470	-11,294
gain from change in fair value of warrant liability																49,559	351,104	-176,778	-1,066,522	442,269	918,801	-616,038	-1,274,156	-1,619,587	-16,065	316,545	981,923	656,523	3,136,265			360,285				294,356
patent expenses																	193,258	174,655	165,996	176,167	193,334	198,239	164,102	174,203	182,597	182,299	173,580	182,310	187,916	206,656	186,028	178,332	218,472	221,475	250,857	197,017
loss on extinguishment of term loan																									-4,981,461
interest expense																									-3,016,817	-3,898,367	-3,971,952	-3,971,031	-3,928,418	-3,962,100	-3,924,124	-3,843,161	-3,748,818	-3,762,240	-3,737,175	-3,652,496	-3,608,916	-2,290,526	-94,776	-10,214				-13,315	-253,412	-86,223	-105,149	-123,609	-140,829	-164,016	-293,438	-376,323	-373,555
diluted (loss) per share																									-0.11
basic earnings per share																													0.02	0.64	4.85																							-0.06	-0.06	-0.08		-0.11		0.47
lease termination																																			1,225,421
loss from change in fair value of warrant liability																														-1,651,121	-2,328,674		-3,303,114
diluted earnings per share																														0.65	4.71																							-0.06	-0.06	-0.08		-0.11		0.44
loss per share: basic and diluted																																-0.09	-0.15	-0.083	-0.12	-0.1	-0.11	-0.15	-0.17	-0.18	-0.19
weighted-average shares outstanding: basic and diluted																																79,094,230	79,039,000		78,908,929	78,840,312	78,777,144	57,188,503	54,284,296	54,216,604	54,114,296		53,919,896	53,589,268	53,504,296		53,504,296	53,414,296	53,252,155		52,548,997	52,214,824	51,714,146				51,637,770				49,959,345	45,151,774	45,509,375	43,620,212	43,196,362	37,463,255		36,747,909	35,838,346	34,732,625			33,946,494
interest on pharmathene liability																																						952,624	3,566,451	4,259,451
loss from change in fair value of warrant liabilities																																		-156,906	-295,771
reorganization items																																								-327,729	-3,389,173	-1,931,050	-1,948,696	-2,149,981	-1,781,825	-1,824,599	-301,937
patent preparation fees																																					240,597	219,725	230,246	239,690	219,715	246,172	194,444	235,334	333,103	169,833	306,009	226,198	285,736	333,427	329,054	300,581	458,156	793,910	376,877	376,320	336,298	571,219	482,074	413,048	341,827	288,086	234,511	305,661	320,339	349,465	191,144	84,426	109,130	119,861	198,115	133,967	129,605
decrease in fair value warrant liability																																					-626,209
litigation accrual																																										10,072.75	13,553			12,899,226	175,465,718
(increase) in fair value of warrant liabilities																																						-280,382.5	-1,121,530
benefit and (provision) for income taxes																																						-2,173	4,072
litigation accrual expense																																									2,917,187
decrease in fair value of common stock warrants																																															11,532	145,788	156,105	655,109	-734,955	980,289	-974,199	462,735	-15,032	325,012	-436,813	402,043	4,726,054	2,039,851	1,762,958
benefit from income taxes																																										-223,894	-65,910	-88,348	-83,831	408,465	-57,953,045	1,775,017	2,241,295	1,683,633	1,690,028	1,966,336	2,278,442	1,780,368	2,470,346	1,660,720	1,932,719	1,609,270	1,527,275	32,907,988
earnings per share: basic and diluted																																										-0.09	-0.1	-0.12	-0.13	-1.155	-4.49	-0.06	-0.06	-0.063	-0.09	-0.06	-0.09
net income																																																		-4,338,457	-4,901,976	-3,061,080	-4,875,819	-3,188,310	-2,940,391	-4,346,557	-4,052,893	-5,756,989	210,514	23,841,926	-4,701,275	-13,577,129	-4,430,306	-4,571,621	-4,409,458	1,048,362	-1,428,688	-10,353,111	-6,884,501	-1,571,456	-3,028,881	-3,140,736	-858,304
yoy																																																		36.07%	66.71%	-29.57%	20.30%	-44.62%	-1496.77%	-118.23%	-13.79%	-57.60%	-104.75%	-621.52%	6.62%	-1395.08%	210.10%	-55.84%	-35.95%	-166.71%	-52.83%	229.64%	702.11%
qoq																																																		-11.50%	60.14%	-37.22%	52.93%	8.43%	-32.35%	7.25%	-29.60%	-2834.73%	-99.12%	-607.14%	-65.37%	206.46%	-3.09%	3.68%	-520.60%	-173.38%	-86.20%	50.38%	338.10%	-48.12%	-3.56%	265.92%
net income margin %	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	Infinity%	Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%
change in net unrealized gain on short-term investments
comprehensive income																																																		-4,338,457	-4,901,976	-3,061,080	-4,875,819
loss per share																																																									-0.08
loss before benefit from income taxes																																																										-3,767,802.75	-1,316,761	-9,066,062
weighted-average shares outstanding, basic																																																											50,806,284	50,879,599
net income per share																																																													-0.09	-0.29	-0.1	-0.1	-0.1	0.04	-0.04	-0.28	-0.19	-0.05	-0.09	-0.09	-0.03
decrease in fair value of common
stock warrants																																																														-1,535,728	-2,018,644
unrealized gain on securities																																																														972.25	528	3,361	1,323
comprehensive loss																																																														-3,653,580.25	-4,429,778	-4,568,260	-4,408,135
increase in fair value of common stock rights,
common stock warrants, and treasury securities																																																																-1,548,927
increase in fair value of common
stock rights and common stock warrants																																																																	-1,368,516
decrease (increase) in fair value of common stock rights and common stock warrants																																																																		-2,629,264	1,190,714
weighted average shares outstanding: basic and diluted																																																																			37,675,381
increase in fair value of common stock rights and common stock warrants																																																																				-7,763,035
decrease in fair value of common stock rights and common stock warrants																																																																					-3,944,735
increase in fair market value of common stock rights and common stock warrants																																																																						-230,804.25	-912,728
decrease in fair market value of common stock rights and common stock warrants																																																																								-1,096,627	1,086,138
weighted-average shares outstanding: fully diluted																																																																								34,507,090

Balance Sheets:

Quarterly

Annual

Unit: USD	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31

assets
current assets
cash and cash equivalents	145,562,142	154,966,414	171,955,584	182,463,084	162,271,052	155,400,262	99,269,756	106,949,786	143,868,648	150,145,844	71,114,114	76,213,484	115,680,683	98,790,622	109,749,555	114,530,926	153,259,914	103,138,819	92,819,425	98,486,013	106,527,495	117,890,240	78,663,526	53,065,833	77,377,300	65,249,072	78,095,231	100,263,915	102,085,215	100,652,809	103,985,265	10,581,112	13,934,807	19,857,833	25,798,125	30,865,936	30,103,574	28,701,824	20,492,788	78,022,356	104,061,350	112,711,028	129,289,275	115,656,150	95,545,619	99,713,929	104,682,642	99,029,327	107,067,070	91,309,754	105,190,655	32,962,728	24,690,394	32,017,490	22,671,928	34,932,776	42,588,476	49,256,930	12,409,958	5,000,364	3,835,915	6,332,053	5,711,777	6,540,003	8,508,027	14,496,313	1,442,256	1,608,271	1,563,660	2,321,519	2,957,755	5,422,814	5,090,173	6,832,290
accounts receivable	4,501,682	3,263,736	2,490,234	6,486,378	7,185,485	21,166,129	12,089,010	8,954,433	18,127,180	21,130,951	8,050,059	6,026,887	12,316,704	45,406,960	54,925,558	19,598,122	5,338,900	83,650,450	3,822,824	7,206,135	4,001,259	3,340,263	40,398,708	36,611,661	1,685,642	4,167,996	3,217,701	4,128,216	4,099,954	1,959,133	1,539,538	2,128,957	1,263,680	1,802,107	612,166	1,768,981	4,878,631	3,154,370	38,747,077	34,488,734	1,003,154	3,676,730	979,232	769,214	14,272,317	491,632	569,061	742,709	610,420	982,023	741,918	622,789	1,026,599	970,288	1,095,324	1,517,947	1,932,610	2,637,103	1,708,294	1,808,640	1,245,241	3,002,144	1,361,236	3,445,347	3,308,935	2,405,861	2,727,451	2,852,965	1,247,272	1,959,608	2,313,677	1,372,834	551,931	986,489
inventory	56,494,950	49,054,873	48,006,005	35,617,037	59,060,679	49,563,880	62,024,473	55,664,453	63,721,788	64,218,337	64,950,228	50,497,103	42,577,787	39,273,090	31,261,346	16,431,382	16,277,501	19,510,379	29,673,044	19,599,891	20,410,371	20,265,519	10,747,532	14,006,986	16,342,014	9,652,855	3,931,161	2,390,487	2,017,077	2,908,210	2,908,249	2,908,249	2,983,249	2,983,249	2,983,249	15,416,808	19,119,555	26,209,964	17,751,519	28,931,893	22,841,861	12,447,088	1,091,948	8,770,488	14,815,835	19,044,477	18,126,911	16,845,607	17,075,545	20,515,349	16,988,019	18,452,502	13,148,805	17,641,922	17,357,337	8,859,970	923,195
prepaid expenses and other current assets	4,966,957	5,571,841	5,293,648	4,636,464	5,104,614	4,914,613	7,302,979	4,906,577	2,174,993	3,496,028	1,856,291	1,560,626	1,958,508	2,315,672	964,065	3,083,027	2,232,989	2,453,444	2,622,254	1,774,218	1,950,149	2,112,069	1,290,388	1,382,499	2,617,852	5,234,000	2,324,439	3,503,932	3,875,130	4,317,615	1,134,925	1,389,933	1,900,566	2,019,999	1,092,396	571,646	932,003	954,426	9,586,430	2,124,292	552,616	623,983	888,481	1,153,130	422,521	898,705	724,174	1,358,018	978,488	750,808	1,061,109	930,507	779,150	801,149					420,467	431,978
total current assets	211,525,731	212,856,864	227,745,471	229,202,963	233,621,830	231,044,884	180,686,218	176,475,249	227,892,609	238,991,160	145,970,692	134,298,100	172,533,682	185,786,344	196,900,524	153,643,457	177,109,304	208,753,092	128,937,547	127,066,257	132,889,274	143,608,091	131,100,154	105,066,979	98,022,808	180,041,785	98,621,732	121,534,950	123,538,666	121,289,845	113,663,346	122,376,221	30,932,438	37,364,493	40,894,746	58,945,660	65,172,653	69,159,474	86,577,814	143,567,275	128,458,981	129,458,829	139,510,700	133,168,731	131,307,728	129,804,671	124,102,788	129,734,471	133,333,724	123,941,842	143,853,152	145,613,525	103,530,458	84,946,176	42,540,233	46,578,955	46,636,330	52,978,703	14,538,719	17,240,832	20,423,847	24,702,564	21,203,288	19,341,053	21,239,333	23,486,546	5,673,519	5,925,949	4,969,840	6,255,092	7,190,484	7,408,692	5,763,514	7,948,894
property, plant and equipment	1,673,973	1,090,824	1,196,803	1,049,022	1,188,008	1,298,423	1,411,315	1,517,270	1,193,237	1,331,708	1,469,298	1,605,222	1,717,193	1,848,314	1,979,517	2,109,720	2,238,431	2,365,957	2,468,463	2,597,296	1,986,888	2,103,990	2,236,668	2,366,135	2,500,641	2,618,303	2,749,758	2,859,865	2,987,432	171,274	117,864	132,574	108,850	138,640	119,735	262,966	263,302	299,477	330,118	372,779	413,848	449,825	457,457	446,581	753,158	831,936	913,309	1,000,542	1,084,650	1,382,073	1,236,373	1,143,651	1,158,327	987,869	774,739	855,208	899,036	818,992	794,468	894,258	1,024,517	1,150,257	1,295,478	1,651,810	1,265,531	1,225,656	1,309,486	1,319,334	1,247,196	1,360,018	1,425,979	1,418,021	1,317,265	1,479,678
deferred tax asset	5,086,458	4,428,519	1,560,453	3,967,201	11,132,552	10,854,702	12,104,765	11,611,925	11,011,668	11,048,118	7,897,576	7,591,743	6,733,810	6,250,385				2,422,607				2,544,053				14,151,002				11,733,385		2,441,740	2,441,720	2,431,963
goodwill	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334	898,334
other assets	203,362	192,893	202,015	212,696	226,485	240,683	253,605	2,155,793	2,149,482	2,083,535	2,144,938	2,117,360	2,041,240	252,546	261,814	249,170	265,433	286,585	306,722	392,665	419,448	676,923	702,885	901,906	847,983	856,766	862,979	929,963	992,966	1,058,880	1,095,199	789,913	702,167	702,167	642,083	642,083	642,083	642,083	642,083	641,564	1,989,520	1,989,520	1,989,520	1,989,520	1,989,520	1,989,520	1,991,512	1,999,431	2,024,555	2,078,159	2,137,433	2,202,294	2,124,931	2,181,720	1,625,800	1,625,800	277,844	535,417	371,748	281,608	280,648	280,648	274,713	268,665	312,252	304,751	283,975	279,902	290,893	283,856	282,712	270,475	267,975	261,766
total assets	219,387,858	219,467,434	231,603,076	235,330,216	247,067,209	244,337,026	195,354,237	192,658,571	243,145,330	254,352,855	158,380,838	146,510,759	183,924,259	195,035,923	204,224,075	159,940,495	184,546,643	214,726,575	135,563,352	133,686,025	138,766,538	149,831,391	141,422,152	120,416,954	118,574,463	198,566,190	203,011,437	203,092,260	206,439,348	203,443,741	143,727,321	128,340,625	133,135,253	144,670,379	148,726,158	156,030,474	160,820,485	160,981,977	162,837,339	201,668,556	184,796,318	185,732,936	197,165,006	182,462,827	173,238,862	166,385,335	164,715,384	209,471,589	214,787,829	193,824,234	201,569,656	177,014,114	128,726,504	105,836,130	92,051,992	92,640,990	89,027,621	90,380,477	50,784,094	51,968,582	22,627,346	27,031,803	23,671,813	22,159,862	23,715,450	25,915,287	8,165,314	8,423,519	7,406,263	8,797,300	9,797,509	9,995,522	8,247,088	10,588,672
liabilities and stockholders’ equity
current liabilities
accounts payable	6,306,482	824,522	5,032,898	1,192,161	1,230,039	1,340,337	1,260,762	1,033,123	2,523,350	1,456,316	564,272	1,081,337	1,139,853	3,355,268	2,445,390	1,214,617	1,778,359	2,028,004	9,962,965	675,403	446,795	1,278,217	1,118,307	630,165	4,765,817	3,054,032	2,251,814	1,070,926	2,149,605	1,688,488	894,792	1,412,595	432,207	1,328,867	1,362,331	3,475,102	2,259,096	2,517,072	2,925,464	9,916,911	8,493,678	3,944,476	3,174,820	4,780,691	3,553,191	3,384,310	680,930	1,628,237	4,343,762	5,064,380	6,826,552	16,258,393	8,588,832	10,189,917	10,613,539	10,045,821	3,903,352	2,278,316	2,218,881	1,377,339	2,293,459	2,884,259	1,415,251	4,403,759	3,963,926	3,458,013	2,979,389	2,810,559	2,054,892	1,806,073	1,155,464	999,216	949,204	1,321,146
accrued expenses and other current liabilities	6,529,847	6,520,057	9,472,862	7,107,421	16,226,824	5,640,110	7,184,514	6,533,033	6,122,929	10,181,810	30,125,855	17,894,986	16,001,327	16,852,781	15,887,359	14,844,830	4,653,420	9,252,812	8,979,128	7,295,055	7,064,722	9,205,293	15,182,437	14,931,370	16,658,698	8,636,911	9,544,060	10,052,283	9,957,736	9,648,917	4,310,917	3,288,437	3,586,195	5,481,579	4,320,994	3,097,915	2,948,349	4,584,752	4,793,300	3,310,723	5,045,138	3,388,608	3,063,410	3,243,021	3,423,697	2,085,995	1,925,696	4,777,869	4,660,747	4,842,393	7,231,697	5,502,750	4,569,305	4,283,849	5,183,230	4,465,450	3,235,129	4,644,461	1,476,875	1,870,688
dividend payable	43,034,458								42,673,509
deferred revenue	8,884,121																															376,562,998	376,030,704	377,641,485	377,447,093	376,480,126	376,203,046	367,483,905	367,123,574	288,293,407	255,474,196	255,258,371	255,094,794	233,739,966	13,528,961	81,799		188,081,857	187,783,380	162,222,189	162,057,530	119,069,235	83,505,866	57,052,020	43,603,902	42,992,609	42,727,036	41,001,110			168,153	190,763	212,874	600,927	662,211	1,570,234	1,319,069	1,329,120	1,337,960	1,302,600	1,302,600
income tax payable	403,517	408,000	96,561	4,178,260	12,687	8,020,366	127,815	82,457	2,703,690	21,690,899	54,432	11,822	1,335,311	1,309,672	9,123,153	634,619	808,771	19,207,042
total current liabilities	65,158,425	17,992,579	24,842,321	22,717,842	27,800,350	25,331,613	22,302,531	21,378,053	74,812,198	54,117,745	30,744,559	18,988,145	18,476,491	21,517,721	27,455,902	16,694,066	7,240,550	30,487,858	18,942,093	7,970,458	7,511,517	10,483,510	16,300,744	15,561,535	21,424,515	91,735,809	11,795,874	11,123,209	12,107,341	11,337,405	5,205,709	381,264,030	4,018,402	6,810,446	13,038,358	13,632,279	12,561,063	13,829,233	108,327,773	216,882,489	13,538,816	7,333,084	6,238,230	8,023,712	6,976,888	7,460,253	4,591,176	8,396,869	11,135,819	12,189,024	17,249,699	30,963,067	15,151,839	15,715,540	15,796,769	14,511,271	7,138,481	6,922,777	3,695,756	3,248,027	3,286,176	4,263,180	2,820,919	9,834,614	8,889,859	9,028,580	9,744,560	10,811,853	8,059,032	4,319,169	3,347,829	1,721,510	1,547,224	2,117,670
other liabilities	2,607,831	2,653,283	3,281,879	3,300,326	3,134,232	3,200,650	3,609,572	3,721,969	3,342,927	3,376,203	3,495,466	3,448,558	3,354,308	3,358,160	3,630,046	3,477,575	3,398,960	3,402,869	3,720,734	3,716,464	2,849,744	2,915,401	3,134,304	2,969,867	2,874,879	2,929,743	3,004,313	3,321,486	3,534,054	1,263,113	903,953	704,858	774,131	840,253	844,407	238,323	225,824	247,989	269,047	290,104	311,161	332,218	351,890	371,561	389,838	405,325	415,895	426,465	437,035	447,605	454,241	348,135	167,093	166,303	161,980	157,182	152,384	147,586	83,699	20,925
total liabilities	67,766,256	20,645,862	28,124,200	26,018,168	30,934,582	28,532,263	25,912,103	25,100,022	78,155,125	57,493,948	34,240,025	22,436,703	21,830,799	24,875,881	31,085,948	20,171,641	16,809,847	40,412,168	29,007,490	16,965,063	16,081,671	20,038,122	28,461,738	26,283,936	30,432,341	100,782,434	100,144,921	99,637,793	100,369,779	100,529,054	91,253,516	469,658,356	467,751,753	467,808,670	461,553,072	459,441,190	456,959,158	448,400,246	476,002,283	505,743,088	479,477,570	470,161,486	461,832,710	441,852,293	426,437,025	412,887,812	392,691,893	197,902,884	200,850,724	176,848,766	182,245,556	153,606,919	103,226,873	76,889,125	60,312,422	58,395,801	51,077,652	48,694,411	4,804,436	9,019,987	11,265,124	14,963,015	15,943,256	18,329,671	16,276,591	15,426,796	19,659,383	21,570,658	13,767,299	7,242,701	7,513,843	4,974,796	3,703,883	5,360,467
commitments and contingencies
stockholders’ equity
common stock	7,172	7,161	7,161	7,154	7,144	7,140	7,137	7,131	7,112	7,109	7,109	7,109	7,154	7,268	7,302	7,302	7,256	7,354	7,431	7,539	7,625	7,720	7,777	7,862	8,105	8,127	8,107	8,105	8,094	8,076	8,032	7,916	7,904	7,904	7,890	7,891	7,878	7,869	5,411	5,411	5,411	5,411	5,411	5,384	5,351	5,351	5,351	5,350	5,334	5,310	5,259	5,240	5,212	5,164	5,164	5,164	5,164	5,164										3,727	3,616	3,538	3,566	3,564	3,396	3,394
additional paid-in capital	242,057,171	241,885,214	241,112,674	240,580,034	239,371,718	238,635,635	238,033,324	237,502,156	236,766,447	235,795,420	235,332,951	234,873,128	234,366,497	233,957,767	233,271,351	232,942,666	226,426,529	226,070,308	225,761,819	225,678,876	225,211,481	224,978,430	221,587,384	221,380,828	221,057,307	220,808,037	221,388,212	220,770,338	220,222,959	218,697,872	220,647,968	214,906,962	214,556,941	214,229,581	214,238,249	213,838,069	213,608,687	213,714,154	177,530,037	177,376,807	177,204,236	177,008,371	176,675,169	176,322,914	175,940,813	175,483,180	174,952,893	174,421,347	173,841,500	173,498,028	171,508,253	170,689,389	169,720,774	152,340,303	151,944,558	151,509,784	150,868,007	150,551,211	149,087,836	146,267,297	138,522,944	134,524,304	116,607,389	103,737,034	102,776,129	101,417,677	80,483,967	77,402,300	73,835,402	72,156,614	71,314,197	71,022,378	67,404,289	67,230,987
accumulated deficit	-90,442,741	-43,070,803	-37,640,959	-31,275,140	-23,246,235	-22,838,012	-68,598,327	-69,950,738	-71,783,354	-38,943,622	-111,199,247	-110,806,181	-72,280,191	-63,804,993	-60,140,526	-93,181,114	-58,696,989	-51,763,255	-119,213,388	-108,965,453	-102,534,239	-95,192,881	-108,634,747	-127,255,672	-132,923,290	-123,032,408	-118,529,803	-117,323,976	-114,161,484	-115,791,261	-168,182,195	-556,232,609	-549,181,345	-537,375,776	-527,073,053	-517,256,676	-509,755,238	-501,140,292	-490,700,392	-481,456,750	-471,890,899	-461,442,332	-441,348,284	-435,717,764	-429,144,327	-421,991,008	-402,934,753	-162,857,992	-159,909,729	-156,527,870	-152,189,412	-147,287,434	-144,226,355	-123,398,462	-120,210,152	-117,269,759	-112,923,202	-108,870,309	-103,113,320	-103,323,833	-127,165,760	-122,464,485	-108,887,356	-99,914,571	-95,342,950	-90,933,492		-90,553,166	-80,200,054	-70,605,553	-69,034,097	-66,005,216	-62,864,480	-62,006,176
total stockholders’ equity	151,621,602		203,478,876	209,312,048	216,132,627		169,442,134	167,558,549	164,990,205		124,140,813	124,074,056	162,093,460		173,138,127	139,768,854	167,736,796		106,555,862	116,720,962	122,684,867		112,960,414	94,133,018	88,142,122		102,866,516	103,454,467	106,069,569													-284,428,550	-264,667,704	-259,389,466	-253,198,163	-246,502,477	-227,976,509	11,568,705	13,937,105	16,975,468	19,324,100	23,407,195	25,499,631	28,947,005	31,739,570	34,245,189	37,949,969	41,686,066											-6,361,036	1,554,599	2,283,666	5,020,726	4,543,205	5,228,205
total liabilities and stockholders’ equity	219,387,858		231,603,076	235,330,216	247,067,209		195,354,237	192,658,571	243,145,330		158,380,838	146,510,759	183,924,259		204,224,075	159,940,495	184,546,643		135,563,352	133,686,025	138,766,538		141,422,152	120,416,954	118,574,463		203,011,437	203,092,260	206,439,348													185,732,936	197,165,006	182,462,827	173,238,862	166,385,335	164,715,384	209,471,589	214,787,829	193,824,234	201,569,656	177,014,114	128,726,504	105,836,130	92,051,992	92,640,990	89,027,621	90,380,477											7,406,263	8,797,300	9,797,509	9,995,522	8,247,088	10,588,672
liabilities and stockholders' equity
deferred iv tpoxx® revenue		10,240,000	10,240,000	10,240,000	10,330,800	10,330,800	13,729,440	13,729,440	20,788,720	20,788,720
stockholders' equity
total stockholders' equity		198,821,572				215,804,763				196,858,907				170,160,042				174,314,407				129,793,269				97,783,756																																	45,979,658	42,948,595	11,362,222	12,068,788	7,728,557	3,830,191	7,438,859	10,488,491	-11,494,069	-13,002,120
total liabilities and stockholders' equity		219,467,434				244,337,026				254,352,855				195,035,923				214,726,575				149,831,391				198,566,190																																	50,784,094	51,968,582	22,627,346	27,031,803	23,671,813	22,159,862	23,715,450	25,915,287	8,165,314	8,423,519
warrant liability																	6,170,337	6,521,441	6,344,663	5,278,141	5,720,410	6,639,211	9,026,690	7,752,534	6,132,947	6,116,882	6,433,427	7,415,350	8,071,873	12,380,939	10,729,818	14,408,991	14,769,276	11,466,162	7,355,033	7,059,262	7,353,618	6,727,409
deferred income taxes															4,183,886	3,039,814	4,035,141		2,952,286	2,731,473
deferred tax assets																					2,572,594		6,484,111	11,183,600	16,304,697		12,799,060	12,388,524	11,227,707		27,952,578												7,261,764	6,819,749	6,251,436	5,655,928		11,758,810	7,602,201	10,383,908	19,420,266	35,047,827	33,657,972	33,515,327	740,439	726,203	731,807	727,772
restricted cash and cash equivalents, short-term																										95,737,862									10,408,810	10,322,289
term debt, current																										80,044,866
total debt, current
restricted cash and cash equivalents, long-term																																			9,430,016	12,091,399
long-term debt																											78,911,307	77,777,748	76,656,511	75,547,597	74,414,036	73,280,477	72,159,240	71,050,324	69,916,765	68,783,206
restricted cash, short-term																											11,053,200	11,248,400	11,461,290	11,452,078	4,095,369	11,028,824	10,850,136	10,701,305
restricted cash, long-term																											87,079,574	64,480,624	66,794,243	68,292,023		1,701,843	3,754,940	6,542,448
deferred costs																																94,339,146	94,296,804	96,592,334	96,741,244	83,190,032	79,038,559	72,649,277	74,388,990	56,188,604	53,035,635	52,936,428	54,308,995	45,959,661	38,290,122	32,860,874	32,809,441	30,097,583	29,176,756	22,583,202	21,887,652	14,234,754	8,669,379	2,841,534	2,397,811	1,937,671	1,506,692
liabilities and stockholders' equity/
stockholders' equity/
total stockholders' equity/																														102,914,687
total liabilities and stockholders' equity/																														203,443,741
liabilities and stockholders’ equity/
stockholders’ equity/
total stockholders’ equity/																															52,473,805
total liabilities and stockholders’ equity/																															143,727,321
liabilities and stockholders’ deficiency
stockholders’ deficiency
total stockholders’ deficiency																																-341,317,731	-334,616,500	-323,138,291	-312,826,914	-303,410,716
total liabilities and stockholders’ deficiency																																128,340,625	133,135,253	144,670,379	148,726,158	156,030,474
revenues
research and development																																2,661,216	1,747,934	12,268,960	1,390,254	4,264,561																																	1,925,777		1,862,557	1,731,958		6,698,717
operating expenses
selling, general and administrative																																2,880,394	3,056,546	12,303,050	3,093,926	3,058,244																																	2,059,693		945,347	1,165,071		3,704,058
patent expenses																																178,332	218,472	909,946	250,857	197,017
total operating expenses																																6,370,907	6,282,845	31,118,129	7,041,039	8,323,099																																	4,866,205		3,996,935	3,799,165		14,161,824
operating income																																-3,709,691	-4,534,911	-18,849,169	-5,650,785	-4,058,538																																	-2,940,428		-2,134,378	-2,067,207		-7,463,107
gain from change in fair value of warrant liability																																360,285				294,356
interest expense																																-3,843,161	-3,748,818	-14,758,140	-3,737,175	-3,652,496
other income																																144,152	2,235	16,788	2,021	8,066																																	662		18,225	23,098		394,249
income before income taxes																																-7,048,415	-11,584,608	-38,329,274	-9,681,710	-7,408,612
benefit from income taxes																																-2,849				-92,825
net and comprehensive loss																																-7,051,264	-11,582,256	-36,235,484	-9,816,378	-7,501,437
loss per share: basic and diluted																																-0.09	-0.15		-0.12	-0.1
weighted-average shares outstanding: basic and diluted																																79,094,230	79,039,000		78,908,929	78,840,312																																	35,838,346					33,330,814
income from change in fair value of warrant liability																																	-3,303,114
benefit/(provision) for income taxes																																	2,352	2,093,790
deferred income tax liability																																			306,449	307,256	307,256	286,066	281,889	277,088	277,895	265,643	7,519,847	7,073,916	6,500,992	5,900,468	240,973														188,062	175,175
litigation expense
lease termination																																		1,225,421	1,225,421
interest on pharmathene liability
income from increase in fair value of warrant liability																																		-4,738,753
backstop fee
reorganization items
loss per common share: basic and diluted																																		-0.46
weighted-average common shares outstanding: basic and diluted																																		78,874,494
income from change in fair value of warrant liabilities																																			-295,771
(provision)/benefit for income taxes																																			-134,668
restricted cash and cash equivalents-short term																																					10,138,890	10,138,890
restricted cash and cash equivalents-long term																																					14,805,554	17,333,332
liabilities and stockholders’ deficit
loan payable																																					67,661,969	66,553,053
stockholders’ deficit
total stockholders’ deficit																																					-296,138,673	-287,418,269	-313,164,944	-304,074,532	-294,681,252
total liabilities and stockholders’ deficit																																					160,820,485	160,981,977	162,837,339	201,668,556	184,796,318
liabilities subject to compromise																																									209,875,502	206,972,170	192,627,949	192,643,138	399,040,346	399,039,967	386,944,313
pharmathene liability																																							93,654,855	203,654,855
warrant liabilities																																							6,954,154
restricted cash																																														4,000,000	4,000,000
current portion of long term debt																																														1,989,948	1,984,550	1,979,231	1,973,990	1,968,826	1,963,738	8,958,725	1,454,249	954,738
current common stock warrants																																																		313,425				287,036
long term debt																																															499,536	997,693	1,494,490	1,989,948	2,484,086	2,976,924	3,468,481	3,955,262
common stock warrants																																																11,532	157,320		1,227,712	243,199	539,453		749,771	734,739	1,059,751	622,938	1,024,981	5,751,035	7,790,886	10,524,660	13,122,337	4,082,000	3,640,000	3,260,000	4,520,000	5,670,000	3,870,000	2,923,532	4,166,014	3,253,286	2,156,659	3,242,797
receivables from long-term contract																																																						3,771,219
receivables from long term contract																																																			451,185	57,597,172	30,227,538
prepaid expenses																																																							675,205	542,059	460,242	356,898			343,141	369,017	381,487	605,903	608,450	1,585,072	1,503,812	1,464,713	1,577,550	1,392,607	1,337,694	84,794	121,410	130,115
short term investments																																																												9,999,850	14,999,550	14,999,350	13,748,788	8,749,800	8,749,925	4,999,300
deferred tax liability
accumulated other comprehensive income																																																														4,067	3,889	3,361	1,323
deferred income tax asset																																																											34,180,825	32,653,550
common stock (.0001 par value...																																																																			3,818
51,418,518 and 49,019,433 issued and outstanding at september 30, 2011,
and december 31, 2010, respectively)																																																											5,142	5,131	5,038
51,314,017 and 49,019,433 issued and outstanding at june 30, 2011,
accrued expenses																																																													824,564	1,188,158
50,381,142 and 49,019,433 issued and outstanding at march 31, 2011,
49,019,433 and 43,061,635 issued and outstanding at december 31, 2010,
and december 31, 2009, respectively)																																																														4,902	4,635	4,367	4,357
accrued expenses and other																																																															1,192,794	747,928	623,722	740,333	926,102	1,002,174	796,180	1,210,496	889,765	722,294	551,220	594,524
46,346,003 and 43,061,635 issued and outstanding at september 30, 2010,
43,671,893 and 43,061,635 issued and outstanding at june 30, 2010,
other current assets																																																																	63,996
43,573,727 and 43,061,635 issued and outstanding at march 31, 2010,
deferred transaction costs																																																																					581,358	581,358	581,358	528,250
43,061,635 and 35,383,720 issued and outstanding at december 31, 2009
and december 31, 2008, respectively)																																																																		4,306
accumulated deficit (see note 2																																																																			-91,981,854
patent preparation fees																																																																					109,130		198,115	133,967		515,263
decrease (increase) in fair value of common stock rights and common stock warrants																																																																					-3,944,735
net income																																																																					-6,884,501		-3,028,881	-3,140,736		-5,638,557
net income per share																																																																					-0.19		-0.09	-0.09		-0.17
siga technologies, inc.
consolidated statements of operations
for the years ended december 31, 2008, 2007 and 2006
increase in fair market value of common stock rights and common stock warrants																																																																							-912,728	-1,096,627
weighted-average shares outstanding: basic																																																																							35,109,434	34,507,090
weighted-average shares outstanding: fully diluted																																																																								34,507,090
accrued bonuses																																																																									46,800	202,000
intangible assets
notes payable
non-current portion of notes payable
decrease (increase) in fair market value of common stock rights and common stock warrants																																																																										1,430,301

Cashflow Statements:

Quarterly

Annual

Unit: USD	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31

cash flows from operating activities:
net loss	-3,454,252												-918,255				-361,049				-812,105											-7,051,264	-11,582,256	-10,302,723	-9,816,377	-7,501,438	-8,614,946	-10,439,900	-9,243,642	-9,565,851	-10,448,567																-4,052,893				-4,701,275	-13,577,129	-5,637,131	-4,571,621	-4,409,458	1,048,362	-1,428,688	-10,353,112	-6,884,501	-1,571,456	-3,028,881	-3,140,736	-858,304
adjustments to reconcile net loss to net cash from operating activities:
depreciation and other amortization	149,949	146,518	141,795	138,986	135,308	130,729	128,382	140,839	138,471	137,591	135,924	133,657	131,121	131,203	130,203	128,711	127,526	128,701	128,833	134,008	130,826	132,678	129,467	134,506	133,163	131,457	130,251	127,565	137,724	20,991	14,710	4,139	29,790	26,977	29,375	39,662	36,175	43,571	42,660	43,592	44,452	48,213	52,290	68,076	78,778	83,524	87,233	89,698	91,106	143,760	116,618	104,625	98,134	111,650	98,735	105,619	103,354	103,020	117,954	182,132	165,182
stock-based compensation	752,965	772,540	774,104	1,234,439	902,280	764,070	813,774	932,287	1,130,010	462,469	459,823	721,440	408,730	686,417	328,685	395,454	368,754	308,489	243,503	467,405	246,412	387,576	380,823	323,533	259,016	396,614	761,096	547,390	408,894	406,898	1,176,558	362,361	327,360	327,360	400,179	285,898	87,594	253,875	153,230	172,571	195,865	348,733	352,282	381,299	491,724	598,469	531,547	606,595	698,851
deferred income taxes	-657,939		2,406,748	7,165,351	-277,850		-492,840	-600,257	36,450		-305,833	-857,933	-483,425		-1,144,072	995,327	-1,612,534		-220,813	-158,879	-28,541		4,699,489	5,121,097	-2,153,695										-807	0	21,190	4,177	4,801	-807	12,252	7,560	3,916	4,611	5,016	3,566	57,741,011	-1,628,027	-2,547,479	-2,347,554	-3,007,595	-1,966,336	-2,278,442	-1,784,017	-2,470,346	-1,660,720	-1,932,719	-1,629,602	-1,526,848	-32,908,415	12,887
deferred revenue	-1,355,879										10,526,805	853,408	-59,644	451,479	3,094,313	6,241,890	-2,971,232	177,306	-67,150	81,002	292,591	-3,357,020	-3,992,779	-2,970,984	11,303,389	-1,813,666	-1,252,074	-73,693	1,277,828			-723,024	169,269	1,449,710	966,967	277,080	8,719,141	360,331	78,830,167	32,819,211	215,825	163,577	21,354,828	220,211,005	13,447,162	81,799	-188,081,857	298,477	25,561,191	164,659	42,988,295	35,563,369	26,453,846	13,448,118	611,293	265,573	1,725,926				-22,610	-22,111	-388,053	-61,284	-908,023	251,165	-10,051	-8,840	35,360
changes in assets and liabilities:
accounts receivable	-1,237,946	-773,502	3,996,143	699,108	13,980,644	-9,077,119	-3,134,577	9,172,747	3,003,771	-13,080,892	-2,023,172	6,289,817	33,090,256	9,518,598	-35,327,436	-14,259,222	78,311,550	-79,827,626	3,383,311	-3,204,876	-660,996	37,058,445	-3,787,047	-34,926,019	2,482,354	-950,295	910,515	-28,262	-2,140,821	-419,595	589,419	-865,277	645,730	-1,189,941	1,156,815	3,109,650	-1,724,261	35,592,707	-4,258,343	-33,485,580	2,673,576	-2,697,498	-210,018	13,503,103	-13,780,685	77,429	173,648	-132,289	371,603	211,080	57,026,858	-26,965,824	-26,512,630	-1,031,257	-191,320	145,350	-1,027,177	-928,809	100,346	-563,399	1,756,903	-1,640,908	2,084,111	-136,412	-903,074	321,590	125,514	-1,605,693	712,336	-948,531	361,757	-820,903	434,558
inventory	-7,440,077	-1,932,217	-12,388,968	22,971,672	-9,496,799	12,666,560	-6,360,020	7,523,995	1,512,118	715,594	-14,497,515	-8,437,867	-3,304,697	-8,044,770	-14,840,670	-176,150	3,097,407	10,092,445	-9,990,997	179,773	-144,852	-9,517,987	3,259,454	2,335,028	-4,086,487	-5,721,693	-1,540,675	-373,409	891,133					0	12,433,559	3,166,747	7,090,409	-8,458,445	11,180,374	-6,090,032	-10,394,773	-11,355,140	7,678,540	6,045,347	4,228,642	-917,566	-1,281,304	229,938	3,439,804	-3,527,330	1,464,483	-5,303,697	4,493,117	-284,585	-8,497,367	-7,936,775	-923,195
prepaid expenses and other assets	594,415	-269,071	-646,503	481,939	-175,802	2,401,287	-494,213	-2,737,895	239,518	-1,578,335	-323,243	321,762	-1,431,530	-1,342,339	2,106,318	-833,775	241,607	188,947	-762,093	202,714	419,395	-795,719	291,131	1,181,431	22,259	-2,903,348
accounts payable, accrued expenses and other liabilities	3,989,352	-7,701,880	6,349,755	-9,636,513	10,409,997	-2,079,717	766,720	-957,798	-3,468,684	2,698,023	1,233,907	1,075,985	-3,011,077	1,151,935	-668,540	3,464,393	-1,881,714	-7,236,892	11,043,055	510,943	-3,330,241	-2,679,117	4,896,426	-2,797,009	-1,624,681	1,634,164																									-7,884,726
income tax payable	-4,483	311,439	-4,081,699	4,165,573	-8,007,679	7,892,552	45,358	-2,621,233	-18,987,210	21,636,468	42,610	-1,323,489	25,639	-7,813,481	8,488,534	-174,152	-18,398,271
net cash from operating activities	-8,663,895	-16,860,808	-9,814,444	63,084,829	7,061,876	56,310,100	-7,383,471	5,953,394	-6,118,216	79,031,730	-5,099,370	-3,580,147	24,447,118	-8,106,225	-4,781,371	-2,207,753	56,706,411	16,102,562	1,628,658	-1,430,272	-4,806,312	45,946,378	31,339,075	-9,088,672	3,322,447	-14,264,300	398,430	-4,347,812	9,379	-3,591,199	86,212,139	-5,187,914	-8,561,703	-5,558,396	-5,052,895	858,191	1,594,802	-24,678,039	-56,235,068	-26,036,471	-8,641,203	-16,516,929	13,696,291	20,098,331	-6,168,310	-4,466,559	10,118,315	-8,068,000	16,592,764	-14,351,747	79,681,400	1,200,625	-8,093,776	4,760,342	-12,250,469	-6,245,953	-6,486,746	37,229,572	-2,898,695	-4,451,885	-4,304,956	-3,430,920	-2,659,609	-1,550,344	-3,184,511	-2,120,672	-2,024,610	-2,273,588	-2,051,959	-801,781	-2,396,508	-2,389,551	-1,610,046
cash flows from investing activities:
capital expenditures	0	-40,539	-289,576	-1	-24,893	-17,838	-22,427	0	0	0	0	0	0	0	0	0	0	-26,196	0	-10,700	-13,724	0	0	0	-15,501	-2	-20,144	3	-8,951	-74,401	0	0	0	-45,882	-14,916	0	0	-12,930	1	-2,523	-8,475	-45,787	0	0	0	-2,152	0	-11,710	-14,184	-289,460	-209,340	-89,949	-268,592	-324,780	-18,266	-61,791	-183,398	-123,477	-18,164	-51,873	-43,509	-16,948	193,909	-558,591	-168,314	-37,015	-111,927	0	0	-50,883	-122,871	-8,462	-158,006
free cash flows	-8,663,895	-16,901,347	-10,104,020	63,084,828	7,036,983	56,292,262	-7,405,898	5,953,394	-6,118,216	79,031,730	-5,099,370	-3,580,147	24,447,118	-8,106,225	-4,781,371	-2,207,753	56,706,411	16,076,366	1,628,658	-1,440,972	-4,820,036	45,946,378	31,339,075	-9,088,672	3,306,946	-14,264,302	378,286	-4,347,809	428	-3,665,600	86,212,139	-5,187,914	-8,561,703	-5,604,278	-5,067,811	858,191	1,594,802	-24,690,969	-56,235,067	-26,038,994	-8,649,678	-16,562,716	13,696,291	20,098,331	-6,168,310	-4,468,711	10,118,315	-8,079,710	16,578,580	-14,641,207	79,472,060	1,110,676	-8,362,368	4,435,562	-12,268,735	-6,307,744	-6,670,144	37,106,095	-2,916,859	-4,503,758	-4,348,465	-3,447,868	-2,465,700	-2,108,935	-3,352,825	-2,157,687	-2,136,537	-2,273,588	-2,051,959	-852,664	-2,519,379	-2,398,013	-1,768,052
cash from investing activities		-40,539	-289,576	-1	-24,893	-17,838	-22,427			0	0
cash flows from financing activities:
payment of employee tax obligations for common stock tendered	-580,997	0	-241,457	-26,113	-166,193	-161,756	-282,600	-196,559	-158,980	0	0			0	0	0	-12,533	0	-160,557	0	-13,361	-7	-174,263	0	-9,746	-976,769	-143,220	0	-56,590	-2,366,150	-1,695,963			-398,015	0	0	-193,052
payment of dividend on vested equity awards	-159,380
cash from financing activities	-740,377	-87,823	-403,480	-42,892,796	-166,193	-161,756	-274,132	-42,870,071	-158,980	0	0	-35,865,366	-7,557,057	-2,852,708	0	-36,521,235	-6,585,316
net increase in cash and cash equivalents	-9,404,272	-16,989,170	-10,507,500	20,192,032	6,870,790				-6,277,196	79,031,730	-5,099,370	-39,467,199	16,890,061																	72,316,276						762,362	1,401,750	8,209,036	-57,529,568	-26,038,994	-8,649,678	-16,578,247	13,633,125	20,110,531	-4,168,310	-4,968,713	5,653,315	-8,037,743	15,757,316	-13,880,901	72,227,927	8,272,334	-7,327,096	9,345,562				36,846,972				620,276			-5,988,286	13,054,057	-166,015	44,611	-757,859
cash and cash equivalents at the beginning of period	154,966,414	0	0	0	155,400,262	0	0	0	150,145,844	0	0	0	98,790,622
cash and cash equivalents at end of period	145,562,142	-16,989,170	-10,507,500	20,192,032	162,271,052	56,130,506	-7,680,030	-36,918,862	143,868,648	79,031,730	-5,099,370	-39,467,199	115,680,683	-10,958,933	-4,781,371	-38,728,988	153,259,914		-5,666,588	-8,041,482	106,527,495													-5,940,292	-5,067,811	762,362	30,103,574	8,209,036	-57,529,568	-26,038,994	104,061,350	-16,578,247	13,633,125	20,110,531	95,545,619	-4,968,713	5,653,315	-8,037,743	107,067,070	-13,880,901	72,227,927	8,272,334	24,690,394	9,345,562	-12,260,848	-7,655,700	42,588,476	36,846,972	7,409,594	1,164,449	3,835,915	620,276	-828,226	-1,968,024	8,508,027	13,054,057	-166,015	44,611	1,563,660	-636,236	-2,465,059	332,641	5,090,173
supplemental disclosure of non-cash investing activities:
purchase of manufacturing equipment	733,862
net income		-5,429,918	-6,365,819	35,483,103	-408,223	45,760,315	1,343,945	1,832,616	10,277,340	72,255,625	-393,066			-811,794	33,040,588			73,207,028	-3,113,357			20,161,426	24,187,955	20,890,158	-8,897,529	-4,502,605			1,629,777	52,390,934												-20,094,048	-5,630,520	-6,573,437	-7,153,319	-19,056,255	-240,076,761	-2,948,263	-3,381,859	-4,338,457	-4,901,978	-3,061,079	-4,875,819	-3,188,310	-2,940,393			-5,756,989	210,513
adjustments to reconcile net income to net cash from operating activities:
write down of inventory		883,350	0			0	0			16,298	44,390			33,026	10,706	22,269	135,471																	0	0
deferred income taxes provision																													505,678	16,219,193	-25,510,838	-19	-9,758
deferred iv tpoxx® revenue		0	0			-3,398,640	0
repurchase of common stock										0	0	-3,515,454	-7,557,057	-2,856,627	0	-3,576,921	-6,572,783	-5,756,972	-7,134,689	-6,600,510	-6,529,348	-6,719,657	-5,567,119	-15,222,795	-993,375																																	-259,720	0
payment of dividend		-87,823	-162,023			0	8,468			0	0			3,919	0
supplemental disclosure of cash flows information:
non-cash lease right-of-use asset and associated liability						0	0
issuance of common stock						0	0	0	417,000
issuance of common stock upon cashless exercise										0																0	0	0	118,500
cash income taxes paid
supplemental disclosure of non-cash financing activities:
gain on change in fair value of warrant liability															0	-49,559	-351,104
conversion of warrant to common stock														0	0
net decrease in cash and cash equivalents							-7,680,030																									-5,228,104	-8,561,703																							-7,655,700	-6,668,454			1,164,449	-2,496,138										-2,465,059	332,641	-1,742,117
loss on change in fair value of warrant liability																		176,778	1,066,522	-442,269	-918,801	616,038	1,274,156	1,619,587	16,065									4,111,129	295,771
loss on extinguishment of term loan																						0	0	0	4,981,461
non-cash interest expense																						0	0	0	887,132	1,133,559	1,133,559	1,121,237	1,108,916	1,133,561	1,133,559	1,121,237	1,108,916	1,133,559	1,133,558	1,121,238	1,108,916					0	0	0	10,052	5,863	7,162	8,444	9,706
repayment of term loan																						0	0	0	-85,913,459
cash, cash equivalents and restricted cash at the beginning of period																0	103,138,819	0	0	0	117,890,240	0	0	0	160,986,934	0	0	0	180,396,910	0	0	0	37,101,586
net increase in cash, cash equivalents and restricted cash																-38,728,988	50,121,095								-83,609,634
cash, cash equivalents and restricted cash at end of period																						39,226,714	25,597,693	-24,311,467	77,377,300	-15,241,071	235,066	-4,347,809	180,340,748	72,316,276	84,768,855	-5,228,104	28,539,883
cash income taxes paid (refund)
loss on inventory																			-82,156
net cash from investing activities																			0	-10,700	-13,724	0	0	0	-15,501	-2	-20,144	3	-8,951	78,264,425	0			-45,882	-14,916			1,199,661	1	-2,523	-8,475	-45,787	-63,166	0	4,000,000	-2,152	-3,965,000	522,897	-14,184	-289,460	-209,340	-89,949	-268,592	-324,780	-18,266	-1,409,747	-183,398	-135,266	9,981,836	4,949,580	-37,890	-1,262,230	-4,800,990	-555,030	-3,917,616	-5,036,315	-111,927			-50,883	-122,871	-8,462	-158,006
net cash from financing activities																			-7,295,246	-6,600,510	-6,542,709	-6,719,664	-5,741,382	-15,222,795	-86,916,580	-976,769	-143,220	0	-56,590	-2,356,950	-1,443,284			-336,014	0			31,687,414						12,200	-2,000,000	-500,002	-500,000	-492,640	-821,264	760,306	-7,244,133	7,161,658	1,035,272	4,910,000	7,887	0	1,690	-247,334	326,453	666,754	1,846,708	5,313,426	6,632,373	137,350	1,113,841	20,211,044	1,970,522	2,509,986	1,294,100	216,428	54,320	2,730,654	25,935
net decrease in cash, cash equivalents and restricted cash																			-5,666,588	-8,041,482	-11,362,745		25,597,693					-4,347,809	-56,162
net realization of deferred revenue and costs due to fda approval																														0
gain on sale of priority review voucher
net proceeds from sale of priority review voucher
net proceeds from exercise of stock options																														9,200
supplemental disclosure of cash inflows information:
supplemental disclosure of non-cash activities:
conversion of warrants to common stock																											0	0	1,172,801	0
lease termination																																		0
deferred income taxes benefit																										-1,351,942
deferred costs																																-130,088	184,864	148,910	-13,551,212	-4,151,473	-6,389,282	1,739,713	-18,200,386	-3,152,969	-99,207	1,372,567	-8,349,334	-7,669,539	-5,429,248	-51,433	-2,711,858	-920,827	-6,593,554	-695,550	-7,652,898	-5,565,375	-5,827,845	-443,723	-460,140	-430,979	-1,256,620
buy back of stock options																																			0
cash income taxes (refund) paid
increase in fair value of warrant liability																											-981,923	-656,523	-3,136,265		2,328,674	-360,285	3,303,114				626,209
net realization of deferred revenue and costs due to fda approval of oral tpoxx®
deferred income taxes provision benefit
prepaid expenses and other current assets																												371,198	442,484	-3,182,690	255,008	585,633	119,433	-927,603	-520,750	360,357	22,423	1,504,879	-335,013	-1,571,676	71,367	264,498	264,649	-741,974	442,093	-265,440	622,616	-586,131	-7,179	310,301
other assets																												63,001	65,916	36,319								-1,266,509	-519							24,721	7,919	-8,967	19,513	25,183	29,375	36,274	56,789	-555,920	0	0	7,501	-163,669	-90,140			-5,935	-6,048	43,587	-7,501	-20,776	-4,073	10,991	-7,037	-1,144	-12,237	-2,500	-6,209
accounts payable, accrued expenses and other current liabilities																												-910,437	-937,637	2,655,982	-179,554	1,937,946	-2,792,043	-128,198	-1,190,422	1,365,572	-1,894,379	-563,022	-5,508,870	-311,182	6,205,732			465,634	2,087,773	3,261,921	-3,598,679	-2,619,543	-902,264				-1,314,839	-1,323,003	1,285,498	7,372,790	215,704
other liabilities																												-212,570	-244,248	359,160	199,095	-69,273	-66,122	-4,153	-189,835	12,499	-22,165	-21,057	-21,057	-21,057	-21,057			-18,277	-15,487				-10,570	-6,636				4,323	4,798	4,798	4,798	63,887	62,774
non-cash backstop fee
liabilities subject to compromise																																						46,900,000	0	-209,875,502	2,903,332	14,344,221	-15,189	-206,397,208	379	12,095,654
return of collateral for surety bond
net proceeds from equity rights offering - net of offering costs
proceeds from term loan escrow release
debt issue costs
portion of term loan paid directly to pharmathene by the lender in satisfaction of the pharmathene claim; such liability is part of the liabilities subject to compromise line item
cash interest paid on pharmathene liability
fair value of warrant, at issuance date, in connection with loan agreement and recorded as warrant liability
loss on disposal of assets
interest expense on term loan-paid with restricted cash
restricted cash																																										0	0	0	4,000,000	0
net proceeds from exercise of warrants and options																																		62,001								0	0			0	0	7,360	94,675	1,237,497	255,867	161,658	1,213,365	0	7,887	0	1,690	12,386	326,453	1,760,690	1,846,708	10,813,426	1,132,373	137,350	1,113,841	4,145,624	-529,478	2,509,986	1,294,100	216,428	107,428	2,836,573	25,935
net proceeds from equity rights offering-net of offering costs
buy-back of stock options
debt issuance costs
repayment of long-term debt																																										0	0	0	-2,000,000	-500,000	-500,000	-500,000	-500,001	-500,000
excess tax benefit from stock-based compensation
net decrease/increase in cash and cash equivalents
cash and cash equivalents at beginning of period																																		0	0	0	28,701,824	0	0	0	112,711,028	0	0	0	99,713,929	0	0	0	91,309,754	0	0	0	32,017,490	0	0	0	49,256,930	0	0	0	6,332,053	0	0	0	14,496,313	0	0	0	2,321,519	0	0	0	6,832,290
cash interest paid on term loan from restricted cash																																		2,655,073	2,574,863	2,530,755	2,527,778
interest expense on term loan - paid with restricted cash																																			2,574,863	2,530,755	2,527,778
pharmathene liability																																							-110,000,000
payments associated with loan agreement and rights offering
net cash used by financing activities																																					-193,052
gain on sale of assets																																														0	-23,771
proceeds from sale of assets																																														0	35,000
supplemental disclosures of cash flows information:
reclass of common stock warrant liability to additional paid-in capital upon warrant exercise																																																		259,179	0	0	492,191
adjustments to reconcile net loss to net cash from in operating activities:
write-off of leasehold improvements																																											0
increase in fair value of warrant liabilities
fair value of warrants, at issuance date, in connection with loan agreement and recorded as warrant liabilities
increase in fair value of warrants																																														0	-11,532	-145,788	-156,105	-655,109	734,955	-980,289	974,199	-462,735	15,032	-325,012	436,813	-402,043	-4,726,054	-2,039,851	-1,762,958	9,804,095
payment of common stock tendered for employee tax obligations																																														-2	0	0	-415,938	-859	0	0	-178,093
proceeds from the issuance of long-term debt																																																		0
change in excess tax benefit from stock-based compensation
decrease in fair value of warrants
reorganization items																																													-581,190	-366,531
collateral for surety bond																																																						0	0
proceeds from maturity of short term investments																																																										0	10,000,000	15,000,000	15,000,000	13,750,000
purchases of short term investments																																																										-11,789	0	-9,998,547	-14,994,381	-14,995,282	-13,744,899	-8,746,439	-3,749,302
stock based compensation																																																			598,502	555,587	604,985	395,745	426,887	641,777	315,106	1,710,731	2,494,097	7,077,692	1,181,252	196,882	218,846	823,565	244,662	723,154	307,968	725,884	384,766	350,178	184,393	359,353	147,369
amortization of debt discount																																																			12,175	12,919	12,730
prepaid expenses																																																				-13,597	21,999	-125,944	-133,146	-81,817	-103,344	-2,807	11,084	-22,034	25,876	12,470	224,416	2,547	976,622	-81,260	-39,099	112,837	-184,943	-54,913	-1,252,900	36,616	8,705
proceeds from the issuance of debt
remaining grant-date fair value of warrants recorded as other assets
adjustments to reconcile net income to net cash from operating activities
accrued interest on short-term investments																																																											-150	-1,753	-5,819
adjustments to reconcile net loss to net cash from operating activities
proceeds from issuance of securities
adjustments to reconcile net loss to net cash from operating
activities
accounts payable and accrued expenses																																																													-954,394	1,464,372	-2,543,642	564,039	389,302	292,855	92,758	961,661	-165,497	971,340	323,719	174,286	-570,446
reclass of common stock warrant liability to additional paid-in capital
upon exercise																																																											0	0	970,816
accounts payable, accrued expenses, and other current liabilities
depreciation																																																														162,169	162,423	172,312	128,439	120,845	121,775	119,649	112,822	116,844	114,913	-92,294	320,419
deferred transaction costs																																																																						0	-53,108
adjustments to reconcile net loss to net
cash from operating activities:
increase in fair value of rights and warrants																																																																1,548,927	1,368,516
proceeds from short term investments
other current assets																																																																	-63,996
amortization of intangible assets
decrease in fair value of rights and warrants																																																																		-4,776,607			3,944,735
net proceeds from the sale of 2,725,339 shares
of common stock
repayment of notes payable
cash paid for interest on notes payable
proceeds from issuance of securites under letter agreement
decrease in fair market value of rights and warrants																																																																								1,096,627	-1,086,138
non-cash consulting expense
net proceeds from issuance of common stock and derivatives
proceeds from issuance of notes payable
net proceeds from exercise of common stock rights
non-cash supplemental information:
conversion of preferred stock to common stock
cashless exercise of warrants to purchase common stock
increase in fair market value of rights and warrants
loss on impairment of investments
loss on write-off of prepaid investments

SIGA Technologies, Inc(NASDAQ:SIGA)

SIGA Technologies, Inc
(NASDAQ:SIGA)